IRVINE, Calif., Sept. 6, 2006 (PRIMEZONE) -- "It's not unreasonable to expect that developments in biotechnology and health care may begin to come in what will seem a far more rapid pace," stated SmallCap Sentinel analyst D.R. Clark. "The amount of new patients, driven by aging Baby Boomers, will create an influx of capital that will inspire unprecedented research and development."
"Along these lines, CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) appears to be one of the most intriguing and perhaps promising companies that we have covered at SmallCap Sentinel," stated Clark. "Its Cardio Vascu-Grow(tm) product may provide new hope for those suffering with cardiovascular disease -- estimated at over 60 million people in the U.S. alone."
"And the product may also be effective in other applications such as wound healing," Clark added. "This would address the diabetic and elderly market -- both of which would greatly benefit from an agent that could stimulate the growth of new blood vessels in the wound area."
CardioVascular BioTherapeutics is developing drug candidates with Cardio Vascu-Grow as the active ingredient for products for the treatment of a number of diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA clinical trials underway for advanced coronary artery disease for patients who currently have no or limited treatment options, and for impaired wound healing seen in patients with diabetes. CVBT is also conducting a proof-of-concept trial in Europe in patients with chronic back pain believed to be caused by blockage of lumbar arteries.
An informational report featuring Cardiovascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-2-06.html.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is online at www.SmallCapSentinel.com.
The report will address issues affecting companies including Merck Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and AstraZeneca PLC ADS (NYSE:AZN).
Individuals may register to receive free future reports at: http://stockupticks.com/register.html.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties that affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid twenty four thousand dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.